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Background: We have previously reported overexpression of the immunoregulatory protein B7-H3 in colorectal
cancer and that nuclear expression predicted poor outcome in colon cancer patients. The present study was
performed to examine the prognostic role of B7-H3 in an independent colorectal cancer cohort.
Methods: Using tissue microarrays from 731 colorectal cancer patients, tumour B7-H3 expression was assessed by
immunohistochemistry. Associations with clinicopathological parameters and patient outcome were investigated.
Results: Nuclear expression of B7-H3 in cancer cells was present in 27% of the samples in the total study cohort,
while cytoplasmic/membrane and stromal expression was seen in 86% and 77% of the samples, respectively.
Nuclear B7-H3 had no prognostic relevance in the complete outcome cohort, neither in colon cancer patients.
However, nuclear B7-H3 was significantly associated with reduced recurrence-free survival in TNM stage I colorectal
cancer patients.
Conclusions: Overexpression of B7-H3 in colorectal cancer was confirmed, but in contrast to previous results,
nuclear B7-H3 was not a strong prognostic biomarker in this cohort. The discrepancy might be related to the use
of single-core tissue microarrays for detection of the heterogeneously expressed B7-H3, and the role of B7-H3 in
colorectal cancer still needs further examination.
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Colorectal cancer (CRC) is a major cause of cancer-
related morbidity and mortality worldwide. Yearly more
than one million new cases of CRC are diagnosed and
about 600 000 patients succumb to the disease, and this
makes it the fourth most common cause of cancer deaths
[1]. Surgery is the cornerstone treatment for CRC, and
while node-positive (TNM III) patients generally profit
from adjuvant chemotherapy, no clear survival benefit has
been shown for patients with stage I and II disease [2,3].
However, tumours within the same stage are biologically
and molecularly heterogeneous, and a significant propor-
tion of stage II patients develop metastatic disease despite* Correspondence: vibing@rr-research.no
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article, unless otherwise stated.apparently curative surgery [4,5]. Thus, reliable prognostic
biomarkers are needed to complement the TNM system
in identifying patients with increased risk of disease recur-
rence. Great effort has been made to find such markers.
Microsatellite instability (MSI) [6-8] and loss of the DCC
(Deleted in Colon Cancer) gene [9] are promising can-
didates, but there is not yet sufficient evidence to apply
them in clinical treatment decisions.
B7-H3, an immunoregulatory protein in the B7 family
of T cell co-regulatory molecules [10,11], is overexpressed
in several different cancer forms including CRC [12-20].
The precise role of B7-H3 in tumour immunity is still am-
biguous, as both T cell co-stimulatory and co-inhibitory
effects have been demonstrated [21,22]. Our group has
previously demonstrated that B7-H3 silencing conferred
reduced metastatic capacity and increased chemosensitiv-
ity in both in vitro and in vivo models [23-25], implying
that B7-H3 is involved in cancer progression also via non-ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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work of Wang et al. and Zhao et al., which showed that
knock down of B7-H3 leads to reduced cell migration and
invasion [26,27], as well as increased gemcitabine sensi-
tivity [28].
We have previously evaluated B7-H3 expression in
nearly 300 CRC whole tissue sections (WTSs) and found
that it was expressed in the tumour cell nucleus in about
30% of the tumours [19]. Interestingly, nuclear localisation
of B7-H3 strongly predicted poor outcome in colon can-
cer, suggesting that nuclear B7-H3 might be considered a
new biomarker that could facilitate colon cancer treat-
ment decisions, pending validation of the results in other
CRC cohorts. The aim of the present work was therefore
to evaluate associations between tumour B7-H3 expres-
sion and clinicopathological parameters and patient out-
come in an independent cohort of CRC patients.
Methods
Patient cohort and tissue microarray
Formalin-fixed, paraffin-embedded tumour tissue was pro-
spectively collected for all patients (n = 939) undergoing
primary surgery for CRC at Oslo University Hospital-Aker
between 1993 and 2003. Registration has been controlled
against the Norwegian Cancer Registry. Representative
tumour tissue was collected for TMA construction with
1.0 mm diameter cores. The study was approved by the
Regional Committee for Medical and Health Research
Ethics (REK1.2005.1629).
Two hundred and eight patients were excluded for the
following reasons: not representative or no tumour tissue
(183), technically unsuccessful staining (12), unknown
disease stage (12), and not primary tumour (1). The total
study population thus included 731 patients with histolog-
ically verified primary CRC. The outcome study popula-
tion included 562 patients in TNM stages I-III who had
undergone curative surgery, with 402 (72%) of the tu-
mours localised in the colon and 156 (28%) in the rectum.
Mean patient age at the time of surgery in both the total
and the outcome study cohort was 73 years (range: 30–94
years). Colon cancer patients younger than 76 years and
all rectal cancer patients entered a 5-year follow-up pro-
gram. Patients who were not enrolled in systematic
follow-up (n = 353) would be admitted to the hospital for
symptoms of relapse, and it is assumed that nearly all
relapses would be identified and registered. Further details
have previously been described [29].
Recurrence-free survival was measured from the date
of surgery until diagnosis of locoregional recurrence or
distant metastases within the first 5 years after surgery.
Of the 562 patients in the outcome study cohort, 115
patients (20%) were diagnosed with locoregional recur-
rence or distant metastasis during this period. Patients
without locoregional recurrence or distant metastaseswere censored at time of death. Overall survival was
measured from date of surgery until death. Survival data
were obtained from the National Registry of Norway.
During the total follow-up period 332 patients passed
away. Median follow-up of patients still alive was 9.7 years
(range: 5.2 - 17.3 years).
Immunohistochemistry
Representative cylindrical tissue cores from formalin-fixed
and paraffin-embedded colorectal tumours were selected
by an experienced colorectal pathologist and collected in a
tissue microarray (TMA). The TMA sections were immu-
nostained using the Dako EnVision FLEX + detection sys-
tem (Dako, Glostrup, Denmark). Dako PT link was used
for deparaffinisation and heat-induced epitope retrieval.
Sections were preheated in Dako EnVision FLEX + Target
Retrieval Solution, High pH, and rinsed in Dako wash
buffer according to the manufacturer’s instructions.
Endogenous peroxidase activity was blocked with EnVision
FLEX Peroxidase-Blocking Reagent, before incubation
with mouse monoclonal anti-human B7-H3 antibody (Clone
MIH42, LifeSpan BioSciences, Seattle, WA), at 1:300 for
30 minutes at room temperature. The primary anti-
body signal was amplified by EnVision FLEX +Mouse
(LINKER) before incubation with EnVision FLEX/HRP
Detection Reagent for 30 minutes. Finally, the sections
were incubated with diaminobenzene before they were
counterstained with hematoxylin, rinsed and mounted
in Cytoseal XYL (Thermo Scientific, Waltham, MA).
Negative controls included replacement of the primary
antibody with normal polyclonal mouse IgG of the same
subclass and concentration, and incubations of sections
with mouse monoclonal anti-B7-H3 antibody pre-absorbed
with 10 μg/ml recombinant human B7-H3 (R&D Systems,
Minneapolis, MN). Positive controls (sections from formalin-
fixed and paraffin-embedded colorectal tumour tissue
known to express high amounts of B7-H3) were included
in all series.
The immunostained TMAs were scored microscopic-
ally by the study pathologist (J.M.N), without knowledge
of patient outcome or corresponding clinicopathological
parameters. Nuclear staining in tumour cells was recorded
as an individual variable. As membrane positive tumour
cells typically displayed cytoplasmic staining as well, cyto-
plasmic and membrane staining were recorded as one
variable, as were staining of tumour-associated fibro-
blasts and endothelial cells. Nuclear and stromal staining
was scored as negative (no staining) or positive (nuclear/
stromal staining present). Cytoplasmic and membrane
staining was semi-quantitatively estimated, and graded as
0 (no staining), 1 (less than 10% positive cells), 2 (10-49%
positive cells) or 3 (more than 50% positive cells). For
the statistical analyses the cytoplasmic/membrane B7-H3
scores were divided into negative (no staining) and
Table 1 Baseline clinicopathological data and tumour
expression of B7-H3
Total study
cohort
Outcome study
cohort
Patients Patients
Parameter Number % Number %
Gender Female 389 53 292 52
Male 342 47 270 48
TNM stage I 103 14 103 18
II 307 42 287 51
III 186 25 172 31
IV 135 18 - -
pT 1 27 4 26 5
2 98 13 94 17
3 534 73 410 73
4 72 10 32 6
pN 0 455 63 389 69
1 197 27 135 24
2 74 10 37 7
ND 5 - 1 -
Differentiation Well 72 10 66 12
Intermediate 549 78 426 78
Poor 87 12 55 10
ND 23 - 15 -
Tumour localisation Colon 546 75 402 72
Rectum 180 25 156 28
Unknown 5 - 4 -
Cytoplasmic/
membrane B7-H3
0 104 14 74 13
1 79 11 44 8
2 124 17 101 18
3 424 58 343 61
Nuclear B7-H3 0 534 73 400 71
1 197 27 162 29
Total1 B7-H3 0 94 13 66 12
1 637 87 496 88
Stromal B7-H3 0 171 23 121 22
1 560 77 441 78
Abbreviations: ND not determined, pN pathological nodal stage, pT pathological
tumour stage, TNM tumour node metastasis.
1Nuclear, and/or cytoplasmic/membrane staining.
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The rationale for choosing this cut-off is that the TMA
cores only comprise a small section of the tumour, and
even a few positive cells in the core indicate a B7-H3 posi-
tive tumour.
Statistical analysis
Associations between B7-H3 expression and clinicopatho-
logical parameters were analysed using two-tailed Fisher’s
exact test or linear-by-linear association chi-square test.
Survival analysis was performed according to the Kaplan-
Meier method, and survival was compared using the
log rank test. The SPSS version 18.0 software (SPSS,
Chicago, IL) was used for statistical calculations. P-values
below 0.05 were considered statistically significant. Five
patients had duplicate cores and of these, three had contra-
dictory nuclear B7-H3 score in the two cores. Scoring these
three patients as nuclear positive or negative or excluding
them from statistical analysis did not significantly influence
results, and in the presented results, nuclear score was set
to positive for these cases. For 5 patients in the total study
cohort and 4 patients in the outcome study cohort tumour
localisation was not known, and these were excluded from
statistical analyses involving tumour localisation.
Results
Patient characteristics
Clinical and pathological features for the total and the
outcome study population are summarised in Table 1.
The total study cohort included 389 (53%) females and
342 (47%) males. The majority of the patients was in
TNM stage II (307/42% in the total study cohort and 287/
51% in the outcome study cohort), had pT3 tumours (73%
in both cohorts) and no lymph node metastases (63 and
69%, respectively). Most tumours were intermediately
differentiated (78% in both cohorts). In both cohorts 103
patients had TNM stage I disease.
B7-H3 expression in primary colorectal carcinomas
The immunohistochemical expression levels of B7-H3
are shown in Table 1, and representative microscope im-
ages are shown in Figure 1. The majority of tumours dis-
played cytoplasmic/membrane staining (Figure 1A and B)
(86% in the total study cohort), as well as stromal staining
(Figure 1A) (77% in the total study cohort). Nuclear stain-
ing was seen in 27% of the evaluated samples in the total
study cohort (Figure 1B and C).
Associations between B7-H3 expression and
clinicopathological parameters
No significant associations were found between cancer cell
B7-H3 expression and clinicopathological parameters, as
shown in Table 2. However, absence of stromal B7-H3
expression was associated with advanced TNM stage(p = 0.03) and the presence of lymph node metastases
pN (p = 0.007). We did not observe any differences in
B7-H3 expression in colon versus rectal cancer.
Associations between clinicopathological parameters and
outcome
The prognostic significance of clinicopathological pa-
rameters was investigated by univariate analysis (Table 3).
Figure 1 Representative photomicrographs of colorectal cancer TMA specimens stained with anti-B7-H3 antibody. Panel A shows
predominantly cytoplasmic and stromal staining, panel B shows nuclear and cytoplasmic staining, panel C shows nuclear staining and
panel D shows a B7-H3 negative tumour.
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were significantly associated with the development of
locoregional recurrence or distant metastases within the
first 5 years after surgery. There was a tendency towards
increased recurrence-free survival for colon cancer
patients versus rectal cancer patients, but it did not reach
statistical significance (p = 0.13). In accordance with
the results for recurrence-free survival, TNM stage, pT
and pN were also significantly associated with overall
survival.
Associations between B7-H3 expression and patient
outcome
Univariate analysis did not display significant associa-
tions between B7-H3 expression and patient outcome in
CRC patients (Table 3). In contrast to what was found
in the previous WTS study nuclear B7-H3 had no
prognostic relevance in the complete outcome cohort
(p = 0.62 for recurrence-free survival and 0.5 for over-
all survival), neither when analysing colon (p = 0.88
for recurrence-free survival and 0.64 for overall survival)
and rectal patients (p = 0.5 and 0.52, respectively) separ-
ately (Figure 2). However, in TNM stage I patients there
was a strong association between the presence of nuclear
B7-H3 expression and reduced recurrence-free survival
(p = 0.006, Figure 3), but not with overall survival (p =
0.57, data not shown).Simulated tissue microarray cores from whole tissue
sections
As the previously observed prognostic significance of
nuclear B7-H3 staining could not be confirmed in the
present TMA cohort, we wanted to assess whether the
use of TMAs instead of WTSs to evaluate tumour B7-
H3 expression might have affected the results, and we
looked in more detail at the nuclear expression pattern
in a few of the old WTS sections. Figure 4 shows B7-H3
immunohistochemical staining in two simulated TMA
cores from distinct segments of the WTSs from patient
16 and 30 in the WTS cohort. As is evident in the im-
ages, there is considerable heterogeneity of nuclear B7-H3
expression in the depicted CRC tumour samples, and the
selection of two morphologically representative cores
from each tumour resulted in opposite nuclear B7-H3
score. This example clearly demonstrates the inherent
problem in obtaining TMA cores representative for the
entire tumour.
Discussion
We have previously reported that nuclear B7-H3 protein
expression was strongly and independently associated
with poor prognosis in colon cancer patients [19]. In the
present work we examined immunohistochemical ex-
pression of B7-H3 in TMAs prepared from a large panel
of colorectal carcinomas, and evaluated the associations
Table 2 Associations between B7-H3 expression and clinicopathological parameters – total study cohort
Parameter
Patients number
(%)
Cytoplasmic/membrane
B7-H3
Nuclear
B7-H3
Total1
B7-H3
Stromal
B7-H3
Gender Male 342 (47) 298 (87) 92 (27) 303 (89) 269 (79)
Female 389 (53) 329 (85) 105 (27) 334 (86) 291 (75)
p-value 0.34 1.0 0.32 0.26
TNM I 103 (14) 88 (85) 33 (32) 89 (86) 79 (77)
II 307 (42) 268 (87) 78 (25) 272 (89) 250 (81)
III 186 (25) 161 (87) 58 (31) 165 (89) 137 (74)
IV 135 (18) 110 (81) 28 (21) 111 (82) 94 (70)
p-value 0.29 0.22 0.27 0.03
pT 1 27 (4) 20 (74) 9 (33) 22 (81) 20 (74)
2 98 (13) 86 (88) 32 (33) 86 (88) 73 (74)
3 534 (73) 463 (87) 135 (25) 471 (88) 419 (78)
4 72 (10) 58 (81) 21 (29) 58 (81) 48 (67)
p-value 0.93 0.34 0.72 0.62
pN 0 455 (63) 393 (86) 119 (26) 398 (87) 363 (80)
1 197 (27) 169 (86) 61 (31) 173 (88) 147 (75)
2 74 (10) 62 (84) 16 (22) 63 (85) 49 (66)
p-value 0.58 1.0 0.74 0.007
Differentiation Well 72 (10) 62 (86) 25 (35) 63 (88) 54 (75)
Intermediate 549 (78) 469 (85) 144 (26) 477 (87) 423 (77)
Poor 87 (12) 74 (85) 22 (25) 75 (86) 67 (77)
p-value 0.91 0.21 0.82 0.85
Tumour localisation2 Colon 546 (75) 473 (87) 150 (27) 481 (88) 417 (76)
Rectum 180 (25) 150 (83) 46 (26) 152 (84) 141 (78)
p-value 0.34 0.7 0.2 0.61
The table shows the number/percent of patients in each subcategory, the number/percent of B7-H3 positive patients in each subcategory as well as the p-value
resulting from statistical analysis of associations between B7-H3 expression and each parameter.
1Nuclear and/or cytoplasmic/membrane staining.
2Five patients had unknown tumour localisation, these were excluded from the statistical analyses involving tumour localisation.
Table 3 Associations between survival and
clinicopathological parameters and B7-H3 expression
Univariate analysis
(P-value, log rank test)
Recurrence-free
survival
Overall
survival
Gender 0.26 0.34
TNM stage <0.001 <0.001
pT <0.001 <0.001
pN <0.001 <0.001
Differentiation 0.58 0.38
Tumour localisation1 0.13 0.33
Cytoplasmic/Membrane B7-H3 0.25 0.82
Nuclear B7-H3 0.62 0.50
Total2 B7-H3 0.24 0.90
Stromal B7-H3 0.43 0.84
1Five patients had unknown tumour localisation, these were excluded from
the statistical analyses involving tumour localisation.
2Nuclear and/or cytoplasmic/membrane staining.
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and patient outcome. The main objective was to investi-
gate whether the results from our previous study could be
validated in an independent CRC cohort.
In the present work, nuclear B7-H3 was significantly
associated with reduced recurrence-free survival in TNM
I patients only, contrasting the previous study in which
nuclear B7-H3 was significantly and independently associ-
ated with reduced metastasis-free and overall survival in
colon cancer patients. The inconsistency between present
and previous results on the prognostic impact of nuclear
B7-H3 may have several possible explanations. Differences
between the two examined CRC patient cohorts could
exist, but both were prospectively established from pa-
tients undergoing surgery for primary CRC within the
same time period, and with no substantial differences in
cohort composition (Additional file 1: Table S1). There
was, however, a critical methodological difference between
the two studies, since TMAs were used in the present
Figure 2 Kaplan-Meier survival plots presenting recurrence-free survival (upper row) and overall survival (lower row) based on nuclear
expression of B7-H3 (B7-H3N) in tumour specimens from colorectal cancer (A, D), colon cancer (B, E) and rectal cancer patients (C, F).
Ingebrigtsen et al. BMC Cancer 2014, 14:602 Page 6 of 9
http://www.biomedcentral.com/1471-2407/14/602work compared to WTSs in the previous one. The use of
single, small cores for TMA construction may not be repre-
sentative of large tumours in the colorectum, in particular
when the protein of interest exhibits significant expression
heterogeneity [30,31]. Using the simulated TMAs as exam-
ples, we show that because of heterogeneity of nuclear
B7-H3 expression in the CRC tumour samples, conclu-
sions regarding nuclear B7-H3 status partially depend on
where the core was taken. Similar results have been dem-
onstrated in a study comparing WTSs and TMAs in clear
cell renal cell carcinoma using simulated TMAs. The
number of cores required to adequately represent WTS
quantification was shown to be biomarker specific, and for
B7-H3 2–3 cores appeared necessary [32]. Thus, although
the present cohort represents a large, well-characterized
population-based collection of CRC specimens, heteroge-
neous expression of the protein of interest rendered the
single-core TMA approach questionable in this setting, and
this represents a limitation for the interpretation of the
results.In both the previous and the present study nuclear
B7-H3 staining was detected in nearly one third of the
evaluated tumour samples. While nuclear expression of
B7-H3 in tumour cells so far has been reported by our
group only, several authors have described the prognostic
impact of tumour B7-H3 expression in various other
cancer forms. The results are highly variable and even
conflicting: Most reports indicate that high tumour B7-H3
level is associated with advanced disease and/or poor out-
come [13,14,16,17,20,33,34]. Some investigators report
no associations between tumour B7-H3 and prognosis
[35,36], and some that high tumour B7-H3 expression is
associated with improved outcome [12,15]. Taken together,
this indicates that the role of B7-H3 as a prognostic marker
in cancer in general is undetermined. Though the incon-
sistent findings might be due to methodological issues it
could also be that B7-H3 has different prognostic and
functional roles in different cancer forms.
Nuclear B7-H3 was associated with poor outcome in
TNM I patients in this cohort, and the strongest association
Figure 3 Kaplan-Meier survival plots presenting recurrence-free survival based on nuclear expression of B7-H3 (B7-H3N) in tumour
specimens from colorectal cancer patients in TNM stage I (A), TNM stage II (B) and TNM stage III (C).
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ous cohort was seen in TNM II patients. This might hypo-
thetically point to nuclear B7-H3 as a possible promoter of
progression and metastasis in early stages of CRC. It is well
known that cancer associated proteins can have diverse
roles in the different stages of cancer progression [37,38].
Additionally, differences regarding the expression level and
distribution of a protein between cancer cells and stromalFigure 4 Immunohistochemical staining of colorectal cancer WTS spe
simulated TMA cores from distinct segments of the whole tissue sections f
nuclear negative cores, and the right panels (C, F) show nuclear positive cocells in a tumour may reflect shifts in biological effects.
Hence, that absent stromal B7-H3 was associated with ad-
vanced disease stage at diagnosis might be of some interest.
T cell co-stimulatory effects of B7-H3 have been demon-
strated, and theoretically tumours lacking stromal B7-H3
could escape anti-tumour immunity which would otherwise
impede disease progression [39,40]. On the other hand,
B7-H3 suppression of anti-tumour immunity has alsocimens with anti-B7-H3 antibody. Panels A, C, D and F show
rom patient 16 (B) and patient 30 (E). The left panels (A, D) show
res.
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role of B7-H3 in this setting unclear. Another hypothesis
could be that stromal B7-H3 restrains disease progression
through so far unknown non-immunological mechanisms.
Despite uncertainty regarding the clinical implications of
nuclear and stromal B7-H3 in CRC, our findings may be
important to consider in future studies.
Conclusions
Nuclear B7-H3 was not a strong prognostic biomarker
in CRC in the present study, contrasting previous find-
ings by our group. Because of heterogeneous expression
of nuclear B7-H3, the use of single-core TMAs instead
of WTSs in the present study may have influenced the
results. However, our results and the findings of other
groups might indicate that hypothetically the biological
role of B7-H3 may differ from one tumour type to an-
other, may change during disease progression, and fur-
thermore that the protein might attain different functions
dependent on cell type, microenvironment and subcellular
localisation. Together with data indicating that B7-H3
promotes cancer progression through modulation of im-
portant signaling pathways [24,25] this calls for further
investigation.
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